These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2950060)

  • 21. Effect of oral ofloxacin on fecal bacteria in human volunteers.
    Pecquet S; Andremont A; Tancrède C
    Antimicrob Agents Chemother; 1987 Jan; 31(1):124-5. PubMed ID: 3471178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers.
    Zeiler HJ; Beermann D; Wingender W; Förster D; Schacht P
    Infection; 1988; 16 Suppl 1():S19-23. PubMed ID: 3286510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R; Griggs D; Andrews JM
    Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of the in vitro activity of 6 quinolones on Pseudomonas sp].
    Lesage D; Delisle-Mizon F; Vergez P; Daguet GL
    Pathol Biol (Paris); 1985 May; 33(5):412-5. PubMed ID: 3162141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective in-vitro inhibition of hepatic oxidative metabolism by quinolones: 7-ethoxyresorufin and caffeine as model substrates.
    Valero F; de la Torre R; Segura J
    J Pharm Pharmacol; 1991 Jan; 43(1):17-21. PubMed ID: 1676053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activities of ciprofloxacin, ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim.
    Digranes A; Dibb WL; Benonisen E
    Chemotherapy; 1985; 31(6):466-71. PubMed ID: 2934234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vitro activity of new quinolones against nonfermenters and references to sensitivity tests].
    Grimm H
    Infection; 1986; 14 Suppl 3():S191-5. PubMed ID: 3093387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of ofloxacin on the faecal flora.
    Midtvedt T
    Drugs; 1987; 34 Suppl 1():154-8. PubMed ID: 3481316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mode of action of 4-quinolones and possible mechanisms of resistance.
    Smith JT
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():21-9. PubMed ID: 3542946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of quinolones on caffeine disposition.
    Carbó M; Segura J; De la Torre R; Badenas JM; Camí J
    Clin Pharmacol Ther; 1989 Mar; 45(3):234-40. PubMed ID: 2920498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Ullmann U
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    Infection; 1986; 14 Suppl 3():S196-202. PubMed ID: 3463542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indomethacin/ibuprofen-like anti-inflammatory agents selectively potentiate the gamma-aminobutyric acid-antagonistic effects of several norfloxacin-like quinolone antibacterial agents on [35S]t-butylbicyclophosphorothionate binding.
    Squires RF; Saederup E
    Mol Pharmacol; 1993 May; 43(5):795-800. PubMed ID: 8388990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].
    Dubreuil L; Devos J; Romond C; Bryskier A
    Pathol Biol (Paris); 1985 May; 33(5):421-5. PubMed ID: 3162143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibacterial activity after a single-dose of norfloxacin, ofloxacin and pipemidic acid detected in urine of volunteers.
    Cruciani M; Monzillo V; Navarra A; Tinelli C; Concia E
    Drugs Exp Clin Res; 1988; 14(8):533-7. PubMed ID: 3150350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
    Zeiler HJ
    Drugs Exp Clin Res; 1985; 11(5):335-8. PubMed ID: 2941261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy of ofloxacin in the treatment of otorhinolaryngological infections.
    Baba S
    Infection; 1986; 14 Suppl 4():S327-31. PubMed ID: 3546157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects.
    Gregoire SL; Grasela TH; Freer JP; Tack KJ; Schentag JJ
    Antimicrob Agents Chemother; 1987 Mar; 31(3):375-8. PubMed ID: 3472488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.